MX365325B - Formulación liofilizada de tat-nr2b9c. - Google Patents

Formulación liofilizada de tat-nr2b9c.

Info

Publication number
MX365325B
MX365325B MX2015006784A MX2015006784A MX365325B MX 365325 B MX365325 B MX 365325B MX 2015006784 A MX2015006784 A MX 2015006784A MX 2015006784 A MX2015006784 A MX 2015006784A MX 365325 B MX365325 B MX 365325B
Authority
MX
Mexico
Prior art keywords
nr2b9c
tat
lyophilized formulation
formulations
formulation
Prior art date
Application number
MX2015006784A
Other languages
English (en)
Spanish (es)
Other versions
MX2015006784A (es
Inventor
Jonathan David Garman
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of MX2015006784A publication Critical patent/MX2015006784A/es
Publication of MX365325B publication Critical patent/MX365325B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015006784A 2012-11-28 2013-11-25 Formulación liofilizada de tat-nr2b9c. MX365325B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730952P 2012-11-28 2012-11-28
PCT/US2013/071755 WO2014085349A1 (en) 2012-11-28 2013-11-25 Lyophilized formulation of tat-nr2b9c

Publications (2)

Publication Number Publication Date
MX2015006784A MX2015006784A (es) 2015-10-29
MX365325B true MX365325B (es) 2019-05-29

Family

ID=50828392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006784A MX365325B (es) 2012-11-28 2013-11-25 Formulación liofilizada de tat-nr2b9c.

Country Status (18)

Country Link
US (1) US20140162957A1 (enExample)
EP (1) EP2925338B8 (enExample)
JP (1) JP6427104B2 (enExample)
KR (1) KR102166374B1 (enExample)
CN (2) CN109106941A (enExample)
AU (1) AU2013352437B2 (enExample)
CA (1) CA2892965C (enExample)
DK (1) DK2925338T3 (enExample)
ES (1) ES2725598T3 (enExample)
HR (1) HRP20190707T1 (enExample)
HU (1) HUE043820T2 (enExample)
LT (1) LT2925338T (enExample)
MX (1) MX365325B (enExample)
PL (1) PL2925338T3 (enExample)
PT (1) PT2925338T (enExample)
SI (1) SI2925338T1 (enExample)
TR (1) TR201905787T4 (enExample)
WO (1) WO2014085349A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
WO2016115561A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
US20190134150A1 (en) * 2016-04-27 2019-05-09 Biocells (Beijing) Biotech Co., Ltd. Therapeutic methods for excitatory neurotoxicity-related injuries
CN106619170A (zh) * 2016-10-26 2017-05-10 暨南大学 包含stp和生长因子的活性组合物及其化妆品或护肤品
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2551190A1 (en) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CA2613012A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EA017291B1 (ru) * 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP5801197B2 (ja) * 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
US8099602B2 (en) * 2008-09-26 2012-01-17 Mykonos Software, Inc. Methods for integrating security in network communications and systems thereof
CA2765169C (en) * 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
PT2440231T (pt) * 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
US9629892B2 (en) * 2010-08-12 2017-04-25 Nono Inc. Treatment of penetrative injury to the brain

Also Published As

Publication number Publication date
KR102166374B1 (ko) 2020-10-15
WO2014085349A1 (en) 2014-06-05
HUE043820T2 (hu) 2019-09-30
US20140162957A1 (en) 2014-06-12
CA2892965A1 (en) 2014-06-05
LT2925338T (lt) 2019-05-10
JP2016502537A (ja) 2016-01-28
BR112015012422A2 (pt) 2017-09-12
EP2925338A4 (en) 2016-05-25
SI2925338T1 (sl) 2019-09-30
JP6427104B2 (ja) 2018-11-21
CA2892965C (en) 2021-06-01
EP2925338B1 (en) 2019-03-27
ES2725598T3 (es) 2019-09-25
CN105101986A (zh) 2015-11-25
DK2925338T3 (da) 2019-05-06
CN109106941A (zh) 2019-01-01
MX2015006784A (es) 2015-10-29
HRP20190707T1 (hr) 2019-10-04
TR201905787T4 (tr) 2019-05-21
KR20150094656A (ko) 2015-08-19
PL2925338T3 (pl) 2019-11-29
AU2013352437A1 (en) 2015-07-09
CN105101986B (zh) 2018-09-25
EP2925338B8 (en) 2019-05-22
HK1215793A1 (en) 2016-09-15
EP2925338A1 (en) 2015-10-07
AU2013352437B2 (en) 2018-04-12
PT2925338T (pt) 2019-05-31

Similar Documents

Publication Publication Date Title
MX2015006784A (es) Formulación liofilizada de tat-nr2b9c.
MX2020009633A (es) Sal de cloruro de tat-nr2b9c.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EP4403197A3 (en) Injectable formulations for organ augmentation
MY170671A (en) Glucagon analogues
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
PH12014501866A1 (en) Thermosensitive nanoparticle formulations and method of making the same
TR201004464A2 (tr) Kemik erimesi için formülasyon.
MX350569B (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
EP2870964A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF COLITIET COMPRISING S-ALLYL-L-CYSTEINE AS ACTIVE INGREDIENT AND MEDICAL PREPARATION COMPRISING THE SAME
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
TR201100151A2 (tr) İbandronate formülasyonu.
CA2860159C (en) Peptides targeting receptor activator of nuclear factor-kappa b (rank) and their applications
IN2012CH05549A (enExample)
IN2014DN07839A (enExample)
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin
TR201200215A2 (tr) Geliştirilmiş farmasötik formülasyonlar.

Legal Events

Date Code Title Description
FG Grant or registration